Showing 1741-1750 of 2034 results for "".
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansionhttps://modernod.com/news/euclid-systems-names-key-leadership-hires-and-announces-major-facility-expansion/2480465/Euclid Systems announced two additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-gene
- Abbvie and Regenxbio Announce Collaboration to Advance Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-collaboration-to-advance-gene-therapy-for-retinal-diseases/2480427/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in
- EyePoint Pharmaceuticals Appoints Jay S. Duker, MD, as Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-jay-s-duker-md-as-chief-operating-officer/2480387/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Operating Officer. Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoint’s Board o
- Report: NHS Patients Waiting More Than 9 Months on Average for Cataract Surgery in 2021https://modernod.com/news/reports-nhs-patients-waiting-more-than-9-months-on-average-for-cataract-surgery-in-2021/2480329/Reports from 12 NHS hospitals across London and Bedfordshire have revealed sharp increases in waiting times for cataract surgery from 2019 to 2021. The impact of the COVID-19 pandemic can be seen, as wai
- Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studieshttps://modernod.com/news/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-society-annual-meeting/2480313/Apellis Pharmaceuticals announced that detailed data from the phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.The studies evaluated the efficacy and safety of pegcetacoplan, an investigat
- FYidoctors Makes Expansion into US Markethttps://modernod.com/news/fyidoctors-makes-expansion-into-us-market/2480296/Canadian eye care provider FYidoctors announced that it has expanded its geographic operations into the US marketplace with the addition of six leading eye care clinics throughout the state of California. The foray marks a major company milestone as the first time FYidoctors has ad
- AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-eye-care-collaboration/2479577/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patient
- Maxwell Hosts Recipients of Opening Your Eyes: The Vision Council Scholarship Fundhttps://modernod.com/news/maxwell-hosts-recipients-of-opening-your-eyes-the-vision-council-scholarship-fund/2479480/Last week, three-time Grammy winner, and modern soul star, Maxwell, honored three recipients of the “Opening Your Eyes: The Vision Council Scholarship Fund” at the Times Square EDITION hotel. During the celebratory event, Maxwell, on behalf of The Vision Council, presented three of th